Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H32N2O5 |
| Molecular Weight | 368.4678 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC[C@H](N[C@@H](C)C(=O)N1[C@@H]2CCCC[C@@H]2C[C@H]1C(O)=O)C(=O)OCC
InChI
InChIKey=IPVQLZZIHOAWMC-NPJQDHAYSA-N
InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13+,14-,15+,16-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1457697
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1457697
(±)-3A,7A-di-epi-Perindopril is a mixture of two isomers (S, RR, SS) and (R, SS, RR) each of which is an isomer of the antihypertensive drug perindopril. The first of which has the same activity as the compound while the second one is almost inactive.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1457697 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1457697
dog: 1 mg/kg
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6102289
Created by
admin on Mon Mar 31 23:24:02 GMT 2025 , Edited by admin on Mon Mar 31 23:24:02 GMT 2025
|
PRIMARY | |||
|
145513-32-2
Created by
admin on Mon Mar 31 23:24:02 GMT 2025 , Edited by admin on Mon Mar 31 23:24:02 GMT 2025
|
PRIMARY | |||
|
HYT0OR3WXJ
Created by
admin on Mon Mar 31 23:24:02 GMT 2025 , Edited by admin on Mon Mar 31 23:24:02 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD